Curriculum Vitae
Martin Hadamitzky is professor and head of the preclinical research group at the Institute of Medical Psychology and Behavioral Immunobiology at the Medical Faculty, University of Duisburg-Essen, Germany. He received his PhD at the Department of Neuropharmacology, Brain Research Institute, University of Bremen. After research stays at the Department of Psychiatry, University of California, San Diego (UCSD), the Max Planck Institute for Neurological Research and the Department of Neurology, University of Cologne, and the Institute of Pharmacology, Toxicology, and Pharmacy at the LMU Munich, he started working at the Institute of Medical Psychology and Behavioral Immunobiology in Essen, where he completed his habilitation in 2017.
Research interests
In the institute his research focuses on analyzing the bi-directional communication between the central nervous system and the peripheral physiological systems, by using paradigms of classical conditioning. As second interest, he investigates the occurrence of detrimental neurobehavioral effects emerging following therapy with immunomodulatory drugs. Besides, he coordinates the recently established core Behavioral and Clinical Neuroscience" which is part of the “Graduate School of Biomedical Science” (BIOME) at the University Clinic Essen. BIOME integrates PhD and MD graduate students of the Faculties of Medicine and Biology into a cutting-edge interdisciplinary study program designed to provide an outstanding, globally focused academic education.
Selected publications
Hadamitzky M and Schedlowski M (2022). Harnessing associative learning paradigms to optimize drug treatment. Trends Pharmacol Sci. (In press).
Lückemann L, Hetze S, Hörbelt T, Schedlowski M, Hadamitzky M (2021). Incomplete reminder cues trigger memory reconsolidation and sustain learned immune responses. Brain Behav Immun. 95:115-121.
Lückemann L, Hetze S, Hörbelt T, Schedlowski M, Hadamitzky M (2021). Reconsolidation-like processes abrogate extinction of learned anti-proliferative properties of the mTOR inhibitor rapamycin. Brain Behav Immun. Ahead of print.
Unteroberdörster M, Herring A, Bendix I, Lückemann L, Petschulat J, Sure U, Keyvani K, Hetze S, Schedlowski M, Hadamitzky M (2021). The mTOR Inhibitor rapamycin improves stress-coping in rats with experimentally induced glioblastoma. Neuropharmacology. 184:108424.
Lückemann L, Stangl H, Straub RH, Schedlowski M, Hadamitzky M (2020). Learned immunosuppressive placebo response attenuates disease progression in a rodent model of rheumatoid arthritis. Arthritis Rheumatol. 72: 588-597.
Hadamitzky M, Lückemann L, Pacheco-López G, Schedlowski M (2020). Behaviorally Conditioned Responses in Immunological and Neuroendocrine Functions. Physiol Rev. 100: 357-405.
Lückemann L, Unteroberdörster M, Martínez-Gómez EM, Schedlowski M, Hadamitzky M (2019). Behavioral Conditioning of Anti-Proliferative and Immunosuppressive Properties of the mTOR Inhibitor Rapamycin. Brain Behav Immun. 79: 326-331.
Lasselin J, Schedlowski M, Lekander M, Hadamitzky M (2019). Clinical Relevance of the Immune-to-Brain and Brain-to-Immune Communications. Front Behav Neurosci. 12: 336.
